Panelist Who Backed Avandia Had Financial Ties to Glaxo

A member of the Food and Drug Administration advisory panel that voted to keep the embattled diabetes drug Avandia on the market is a paid speaker for the drug’s maker, GlaxoSmithKline, The Wall Street Journal reports.

The panel member, endocrinologist David Capuzzi, confirmed his relationship with the pharmaceutical giant, but said he does not believe it is a conflict of interest.

“I have not given any talks [to doctors' groups] promoting Avandia,” Capuzzi told the Journal.

The diabetes drug first came under fire in 2007, when a study published in The New England Journal of Medicine said Avandia increased the risk of heart attack by more than 40 percent. Last year, a study funded by the drugmaker did not show an increased risk. Some diabetes patients and doctors have lobbied to keep the drug on the market because of its effectiveness.

The company recently reached a $460 million settlement with about 10,000 plaintiffs who claim that the company hid evidence of the drug’s side effects

Last week, the FDA voted 20-12 to keep the drug on the market, but 17 of the panelists who voted in favor of it either wanted additional warnings about the heart risks the drug poses or tighter prescribing restrictions. Capuzzi was one of the three panelists who wanted Avandia to stay on the market without new warnings or restrictions.

In total, the drugmaker has paid Capuzzi $14,750 for speaking engagements, the Journal reports. He earned $3,750 between April 2009 and March 2010.

Capuzzi said that he told the FDA about his work for the company, but the agency said it is looking to see if the disclosure was made, and if so, why it was not made to the rest of the advisory panel.

Capuzzi said the drug should stay on the market because a major alternative diabetes drug, Actos, may have similar safety issues.

The danger I worried about was that if we pulled Avandia, people might automatically switch to Actos and think it’s all hunky-dory,” he said.

According to the Journal, Actos maker Takeda Pharmaceutical Co. says its drug is safe; the committee members voted overwhelmingly that Actos poses fewer heart-attack risks than Avandia.

Print Print  

Like what we're doing? We'd appreciate your support.

Leave a comment